MPR Weekly Dose 167 — Molluscum contagiosum Tx approved; Xdemvy and Balfaxar approved; Weight loss drug in short supply; Cervical pessary assessed for reducing preterm birth
Single-use application to treat the molluscum contagiosum approved; Xdermvy has gotten the green light to treat demodex blepharitis; warfarin reversal treatment for use in urgent surgery; weight loss ...
28 Juli 202312min
MPR Weekly Dose 166 — Potential Alzheimer drug may slow disease; RSV Tx for neonates, toddlers; Veklury and Brenzavvy approvals expanded; Blood test false negatives
Study supports the benefit of potential new Alzheimer drug; RSV treatment approved for neonates and infants; Veklury approval expanded; a blood test used to diagnose life-threatening heart muscle inju...
21 Juli 202315min
MPR Weekly Dose 165 — OTC Birth Control Pill; Heart Tx Gains Expanded Approval; Gavreto Indication Withdrawn; Albuterol Inhaler Recall; Paclitaxel-Coated Device Analysis
First over-the-counter birth control pill; expanded approval for Leqvio; Gavreto has an indication withdrawn; batches of Albuterol inhalers recalled; results from analysis of paclitaxel-coated devices...
14 Juli 202311min
MPR Weekly Dose 164 — Approvals for Alopecia, Generalized Myasthenia Gravis, and Type 1 Diabetes; Colonoscopy Prep; FDA Deny Application for Pre-Cirrhotic Fibrosis Tx
New approvals for alopecia, generalized myasthenia gravis and type 1 diabetes; New colonoscopy prep option; And FDA denies application for pre-chirrotic fibrosis due to NASH.
30 Juni 202313min
MPR Weekly Dose 163 — COVID-19 Vaccine Authorization Revoked; Injectafer Approved; Lumryz Single Dose for Narcolepsy; Vowst for C. Difficile; Approval for CMV Disease Prevention
FDA revoke Emergency Use Authorization for a COVID-19 vaccine; New approval for treatment of iron deficiency in patients with heart failure; Lumryz now available for excessive daytime sleepiness; Vows...
8 Juni 202313min
MPR Weekly Dose 162 — LRTD Vaccine; Novel Heart Failure Tx; Compounded Semaglutide Concerns; Opioid Use Disorder Tx; Positive Results for Motion Sickness Tx
New vaccine for lower respiratory tract disease; A new treatment for heart failure; Concerns over some compounded semaglutide; New opioid use disorder treatment; Motion sickness Tx shows promise.
2 Juni 202312min
MPR Weekly Dose 161 — First Oral Antiviral Approved for COVID-19; First Topical Tx for Epidermolysis Bullosa; Xacduro and Opvee Approved; Cough Suppressant Recall
First oral antiviral approved for COVID-19; First topical treatment approved for epidermolysis bullosa; Xacduro gets green like for bacterial pneumonia; New nasal spray for opioid overdoses; Child cou...
26 Maj 202315min
MPR Weekly Dose 160 — Labeling Update for Prescription Stimulants; Veozah Approved for Vasomotor Symptoms; FDA Vote on DMD Therapy; Fungal Meningitis Cases in US; Child's Smart Thermometer Recalled
FDA requires label updates for the entire class of prescription stimulants; Novel treatment approved for menopause symptoms; FDA Committee takes votes on potentially accelerated approval of Duchenne m...
19 Maj 202311min
